Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2011 1
2014 2
2017 2
2018 3
2019 1
2020 7
2021 4
2022 1
2023 4
2024 3
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Epidemiology of Gestational Trophoblastic Disease.
Joneborg U. Joneborg U. Hematol Oncol Clin North Am. 2024 Dec;38(6):1173-1190. doi: 10.1016/j.hoc.2024.07.003. Epub 2024 Sep 5. Hematol Oncol Clin North Am. 2024. PMID: 39242293 Review.
Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance.
Pietilä EA, Gonzalez-Molina J, Moyano-Galceran L, Jamalzadeh S, Zhang K, Lehtinen L, Turunen SP, Martins TA, Gultekin O, Lamminen T, Kaipio K, Joneborg U, Hynninen J, Hietanen S, Grénman S, Lehtonen R, Hautaniemi S, Carpén O, Carlson JW, Lehti K. Pietilä EA, et al. Among authors: joneborg u. Nat Commun. 2021 Jun 23;12(1):3904. doi: 10.1038/s41467-021-24009-8. Nat Commun. 2021. PMID: 34162871 Free PMC article.
Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)-European Society of Gynaecologic Oncology (ESGO)-Gynecologic Cancer InterGroup (GCIG)-International Society for the Study of Trophoblastic Diseases (ISSTD).
Lok C, van Trommel N, Braicu EI, Planchamp F, Berkowitz R, Seckl M; EOTTD-ESGO-GCIG-ISSTD Guideline Committee. Lok C, et al. J Clin Oncol. 2025 Jun 20;43(18):2119-2128. doi: 10.1200/JCO-24-02326. Epub 2025 May 13. J Clin Oncol. 2025. PMID: 40359461
Surgical Management of Gestational Trophoblastic Disease.
Coopmans L, Larsson A, Joneborg U, Lok C, van Trommel N. Coopmans L, et al. Among authors: joneborg u. Gynecol Obstet Invest. 2024;89(3):214-229. doi: 10.1159/000534065. Epub 2023 Oct 3. Gynecol Obstet Invest. 2024. PMID: 37788661 Review.
Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer.
Moyano-Galceran L, Pietilä EA, Turunen SP, Corvigno S, Hjerpe E, Bulanova D, Joneborg U, Alkasalias T, Miki Y, Yashiro M, Chernenko A, Jukonen J, Singh M, Dahlstrand H, Carlson JW, Lehti K. Moyano-Galceran L, et al. Among authors: joneborg u. EMBO Mol Med. 2020 Apr 7;12(4):e11177. doi: 10.15252/emmm.201911177. Epub 2020 Mar 2. EMBO Mol Med. 2020. PMID: 32115889 Free PMC article.
Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia.
Ghorani E, Kaur B, Fisher RA, Short D, Joneborg U, Carlson JW, Akarca A, Marafioti T, Quezada SA, Sarwar N, Seckl MJ. Ghorani E, et al. Among authors: joneborg u. Lancet. 2017 Nov 25;390(10110):2343-2345. doi: 10.1016/S0140-6736(17)32894-5. Lancet. 2017. PMID: 29185430 Free article. No abstract available.
29 results